uracil has been researched along with Cardiotoxicity in 3 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cardiotoxicity in the form of cardiac arrhythmia, myocardial infarction, and angina-like symptoms are not rare complications of fluoropyrimidines as 5-Fluorouracil (5FU) and capecitabine." | 3.83 | TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape? ( Barni, S; Bertocchi, P; Petrelli, F; Zaniboni, A, 2016) |
| " This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate." | 2.58 | Fluoropyrimidine-induced cardiotoxicity. ( Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Depetris, I | 1 |
| Marino, D | 1 |
| Bonzano, A | 1 |
| Cagnazzo, C | 1 |
| Filippi, R | 1 |
| Aglietta, M | 1 |
| Leone, F | 1 |
| Bendell, JC | 1 |
| Patel, MR | 1 |
| Yoshida, K | 1 |
| Seraj, J | 1 |
| Weaver, R | 1 |
| Lemech, C | 1 |
| Todaro, TG | 1 |
| Pant, S | 1 |
| Arkenau, HT | 1 |
| Petrelli, F | 1 |
| Barni, S | 1 |
| Bertocchi, P | 1 |
| Zaniboni, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate the Cardiac Safety of Orally Administered TAS-102 in Patients With Advanced Solid Tumors[NCT01867879] | Phase 1 | 44 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for uracil and Cardiotoxicity
| Article | Year |
|---|---|
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Hu | 2018 |
1 trial available for uracil and Cardiotoxicity
| Article | Year |
|---|---|
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Drug Administr | 2016 |
1 other study available for uracil and Cardiotoxicity
| Article | Year |
|---|---|
TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape?
Topics: Cardiotoxicity; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Thymine; Treatment Ou | 2016 |